Bristol Myers Squibb announces topline Results from Phase 3 Independence trial for Reblozyl

Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use

Biocon Biologics expands diabetes portfolio with FDA approval of Kirsty

Emcure Pharmaceuticals, Sanofi India ink distribution agreement to broaden reach of Sanofi's oral anti-diabetic drugs

Waters, BD biosciences unit agree to $17.5 billion merger

The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026

FDA approves Bayer’s Finerenone for new indication in patients with HF and LVEF of ?40%

Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,

India launches nutraceutical trade expo ‘Bharat Nutraverse’

India’s nutraceutical industry is expected to reach over US$ 22 billion in 2025

Lilly partners with API to launch ‘Obesity Gurukul’ in India

The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities

PharmaJet inks MoU with Egypt’s UPA and EVA Pharma to offer needle-free delivery for routine immunization

The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development

WHO, ITU, and WIPO release new report on AI use in traditional medicine

The global TCIM market is expected to reach nearly US$ 600 billion by 2025

Cupid invests in GII Healthcare Investment

GII is a leading investment firm with assets under management exceeding US$ 3.5 billion with presence across Saudi Arabia, UAE, Europe, USA and India